Interestingly, inhibition of glutamine transporter protein solute carrier 1 family member 5 (SLC1A5) increased EGFR degradation via the ubiquitin–proteasome pathway, thereby significantly enhancing the inhibitory effect of cetuximab on CRC proliferation (Ma et al. 2018). Here, UBC is linked to colorectal carcinoma.